EU Regulatory System Attacked Over Quality Of Approvals
Drug Bulletin Says Some Products Should Not Have Been Authorized
If anyone can throw cold water on the claimed benefits of some of Europe's most recently approved medicines, it’s the international drug bulletin, Prescrire. In an assessment of 108 of the pharma industry’s latest offerings, it gives a cautious welcome to some but says that more than half bring nothing new and others could even be dangerous to patients.
You may also be interested in...
Bluebird bio’s gene therapy Zynteglo, Akcea’s antisense drug Waylivra and BioMarin’s enzyme substitution therapy Palynziq were among the novel innovative medicines that were approved in Europe in 2019.
The joint action on ensuring security of medicines supply will be supported by the EU regulators’ shortages task force, which is to track efforts to coordinate member state activities on the supply and availability of medicines.
Hundreds of videos have been sent in by people interested in contributing to the future pandemic treaty proposed by the World Health Organization.